GlassScriptPhysician profile
Trini Tran
NPI 1477164846
$6,338.98
in general payments reported to CMS, 2019-2025
34 companies · $3,325 in 2025
The $3,325 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $57.11 · 2022: $17.29 · 2023: $112 · 2024: $2,827 · 2025: $3,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,264.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $858.60 | 2024-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $784.66 | 2024-2025 | Omnipod |
| Lilly USA, LLC | $732.92 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Ascensia Diabetes Care US INC. | $639.52 | 2024-2025 | |
| Amgen INC. | $412.64 | 2024-2025 | Evenity, Tepezza, Prolia |
| Novo Nordisk INC | $295.70 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Embecta Corp. | $237.43 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Corcept Therapeutics | $234.02 | 2024-2025 | Korlym |
| Abbvie INC. | $226.18 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $215.50 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $214.96 | 2024-2025 | Farxiga |
| Tandem Diabetes Care, INC. | $213.35 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $209.68 | 2025 | |
| Radius Health, INC. | $163.75 | 2024-2025 | Tymlos |
| Mannkind Corporation | $136.38 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $126.41 | 2024-2025 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.27 | 2024-2025 | Jardiance |
| Sequel Med Tech, LLC | $70.52 | 2025 | Twiist |
| Beta Bionics, INC. | $53.09 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Antares Pharma, INC. | $51.65 | 2024-2025 | Xyosted |
| Ibsa Pharma INC. | $50.21 | 2024 | Licart, Tirosint |
| Merck Sharp & Dohme LLC | $35.48 | 2021 | |
| Globus Medical, INC. | $32.92 | 2025 | Senza |
| Ucb, INC. | $28.89 | 2023 | |
| Amneal Pharmaceuticals LLC | $28.83 | 2025 | Unithroid |
| Verity Pharmaceuticals INC. | $27.78 | 2024 | Tlando |
| Kyowa Kirin, INC. | $25.89 | 2024 | Crysvita |
| Alvogen INC | $24.71 | 2024 | Teriparatide |
| Abbott Laboratories | $23.41 | 2025 | Freestyle Libre 3 |
| Therapeuticsmd, INC. | $21.63 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.42 | 2024 | Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $18.61 | 2024 | Isturisa, Signifor Lar |
| Becton, Dickinson and Company | $17.29 | 2022 | |
| Acella Pharmaceuticals, LLC | $16.68 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trini Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.